9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita

9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita

Basement Membrane Zone (BMZ) Architecture & Target Antigens

The dermo-epidermal junction (DEJ) connects the basal keratinocyte cytoskeleton to the underlying papillary dermal extracellular matrix. Blistering in the pemphigoid group and epidermolysis bullosa acquisita results from autoantibodies targeting distinct structural components of this hemidesmosomal-anchoring complex:

Ultrastructural Anatomy of the Hemidesmosome-Anchoring Complex

1. Hemidesmosomal Plaque (Intracellular / Keratinocyte Base):
   • BP230 (Bullous Pemphigoid Antigen 1 / BPAG1-e): A 230-kDa cytoplasmic protein of the plakin superfamily. Anchors keratin intermediate filaments (K5/K14) to the hemidesmosomal inner plaque.
   • Plectin: Linker protein bridging intermediate filaments to integrins.
2. Transmembrane Hemidesmosomal Proteins:
   • BP180 (Bullous Pemphigoid Antigen 2 / BPAG2 / Type XVII Collagen): A 180-kDa type II transmembrane collagenous glycoprotein. The intracellular amino-terminus anchors to BP230 and beta-4 integrin. The extracellular carboxy-terminal ectodomain extends across the lamina lucida into the lamina densa and contains 16 collagen-like domains. The NC16A domain (non-collagenous 16A domain, situated immediately adjacent to the plasma membrane) harbors the immunodominant pathogenic epitopes in bullous pemphigoid.
   • Alpha-6-Beta-4 Integrin (α6β4): Transmembrane heterodimer interacting with plectin, BP180, and laminin 332.
3. Lamina Lucida (Extracellular Clear Zone):
   • Laminin 332 (formerly Laminin 5 / Epiligrin): A heterotrimeric glycoprotein (α3β3γ2 chains) that bridges transmembrane integrins/BP180 to Type VII collagen in the dermis.
4. Lamina Densa (Basal Lamina Proper):
   • Type IV Collagen, Perlecan, and Nidogen.
5. Sub-Lamina Densa (Dermal Fibrous Anchor):
   • Anchoring Fibrils (Type VII Collagen): Composed of anti-parallel homodimers of Type VII collagen molecules that loop around interstitial dermal collagen bundles (Type I and III). The amino-terminal NC1 (non-collagenous 1) domain serves as the primary autoantigenic target in epidermolysis bullosa acquisita (EBA).

Bullous Pemphigoid (BP)

Bullous pemphigoid is the most prevalent autoimmune blistering disease in Europe, with an annual incidence of 15 to 40 cases per million population, rising steeply with advancing age (>150 to 300 cases per million annually in individuals over 80 years).

Epidemiology & Neurological Comorbidities

• Demographic Predilection: Peak onset occurs between 75 and 85 years; childhood or young adult presentations are exceedingly rare.
• Neuro-Dermatological Axis: BP exhibits a striking, biologically validated statistical association with severe pre-existing neurological and neurodegenerative disorders. Meta-analyses show that patients with BP have a several-fold higher prevalence (odds ratios roughly 2- to 10-fold) of:
  • Dementia (Alzheimer's disease, vascular dementia).
  • Parkinson's Disease.
  • Prior Cerebrovascular Accident (Ischemic/Hemorrhagic Stroke) or Hemiplegia.
  • Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
  • Severe Unipolar or Bipolar Depression.
• Molecular Mechanism of Association: BP180 and neuronal isoforms of BP230 (encoded by the dystonin gene, DST) are expressed within human brain tissue (cortical pyramidal neurons and cerebellar Purkinje cells). Neurodegeneration, ischemic stroke, or blood-brain barrier disruption exposes these central nervous system antigens, initiating an autoreactive B-cell immune response. Due to molecular homology, circulating autoantibodies subsequently cross-react with hemidesmosomal epitopes in the skin, culminating in cutaneous bullous pemphigoid years later.

Drug-Induced / Drug-Associated Bullous Pemphigoid

Pharmacological agents can trigger de novo BP or unmask subclinical disease:

1. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins):
   • Agents: Vildagliptin (highest reported odds ratios, up to about 10-fold in some case-control studies), Linagliptin, Sitagliptin, and Saxagliptin.
   • Phenotype: Characteristically exhibits a non-inflammatory, paucicellular phenotype with minimal erythema, scarce tissue eosinophilia, and autoantibodies targeting non-NC16A epitopes of BP180. Blisters may arise after prolonged latency (months to years following drug initiation) and frequently resolve upon gliptin discontinuation.
2. Immune Checkpoint Inhibitors (ICIs):
   • Agents: Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 (atezolizumab, durvalumab) monoclonal antibodies.
   • Phenotype: Eruptions typically emerge 3 to 9 months after starting immunotherapy. BP indicates robust immune activation and often correlates with superior anti-tumor response. High-potency topical steroids or dupilumab are preferred to maintain checkpoint therapy when possible.
3. Loop Diuretics (Furosemide) and Spironolactone.
4. Neuroleptics and Antipsychotics (e.g., phenothiazines).

Clinical Phases and Presentation

• Prodromal (Non-Bullous) Phase: In 20% to 40% of patients, BP begins with an insidious, protracted prodrome lasting weeks to months. It is characterized by excruciating, intractable pruritus accompanied by non-specific cutaneous manifestations: urticarial wheals, eczematous excoriated papules, prurigo-like nodules, or targetoid erythema. Elderly patients are frequently misdiagnosed with senile pruritus, nummular eczema, or scabies before blisters develop.
• Classic Bullous Phase: Characterized by tense, dome-shaped, serous or hemorrhagic bullae ranging from 0.5 to 5 cm in diameter. Bullae arise on normal-appearing skin or atop intensely erythematous, edematous, urticarial plaques. Because the blister roof consists of the entire full-thickness epidermis (subepidermal split), the blisters are firm and tense, persisting intact for days without bursting spontaneously.
• Anatomical Distribution: Symmetrical predilection for the flexor surfaces of the extremities (inner thighs, volar forearms, axillary folds), lower abdomen, and groin. Facial and palmoplantar involvement is uncommon.
• Nikolsky Signs: Nikolsky sign I and II are strictly negative (direct shearing force does not dislodge the tough, full-thickness epidermis).
• Mucosal Sparing: Unlike pemphigus, mucous membrane involvement is uncommon (<10–20%), transient, mild, and non-scarring (limited to superficial oral erosions).

Histopathology & Immunofluorescence Diagnostics

• Histopathology: Biopsy of an early, small, intact tense blister reveals a subepidermal, non-acantholytic blister cleavage beneath the basement membrane. The dermal blister cavity and superficial papillary dermis show a dense inflammatory infiltrate rich in eosinophils, alongside neutrophils, lymphocytes, and histiocytes. In the pre-bullous prodromal phase, biopsy reveals eosinophilic spongiosis (intercellular epidermal edema infiltrated by eosinophils) and dermal papillary eosinophil degranulation along the DEJ.
• Direct Immunofluorescence (DIF): The gold standard test. Biopsy of perilesional normal skin shows continuous, bright linear deposition of IgG (predominantly IgG4 and IgG1) and C3 along the basement membrane zone.
  • Serration Pattern Analysis: High-resolution microscopy distinguishes an n-serrated pattern (arched "roof-like" loops outlining the dermal papillae, indicating antibody localization in the upper lamina lucida/hemidesmosome) from the u-serrated pattern seen in epidermolysis bullosa acquisita.
• Salt-Split Skin Indirect Immunofluorescence (1M NaCl): When normal human skin is incubated in 1.0 M sodium chloride, cleavage occurs selectively through the lamina lucida. Patient serum incubated on this substrate demonstrates IgG autoantibody binding strictly to the epidermal roof of the split (the blister roof), confirming reactivity to hemidesmosomal BP180 or BP230.
• ELISA Serology:
  • Anti-BP180 NC16A ELISA: Positive in >90% of active BP cases. Quantitative index values correlate tightly with clinical blister count, pruritus severity, and clinical activity, serving as a reliable guide for steroid tapering.
  • Anti-BP230 ELISA: Positive in 50–70% of patients; antibodies often persist indefinitely and correlate less reliably with acute inflammatory exacerbations.

European Management Guidelines: The Topical Steroid Revolution

For decades, extensive bullous pemphigoid was managed with high-dose oral corticosteroids (prednisone 1.0 mg/kg/day). However, the elderly, multimorbid BP demographic suffered devastating 1-year mortality rates of 30% to 40%, primarily driven by lethal sepsis, cardiovascular collapse, and corticosteroid-induced complications.

• The Joly European Landmark Trial (NEJM 2002): A multicenter randomized trial comparing whole-body superpotent topical corticosteroids (clobetasol propionate cream 20–40 g/day) against oral prednisone (1.0 mg/kg/day) in extensive bullous pemphigoid demonstrated:
  • Disease control at 3 weeks was achieved in 99% of the topical group versus 91% of the oral prednisone group.
  • 1-Year Overall Survival: 76% with topical clobetasol versus 58% with oral prednisone ($p = 0.02$).
  • Severe complications were substantially less frequent in the topical group.
• Consequently, current EDF and EADV guidelines designate whole-body superpotent topical corticosteroids as first-line therapy for both localized and extensive bullous pemphigoid.

Structured BP Treatment Protocol

1. First-Line Topical Regimen (Extensive BP):
   • Clobetasol propionate 0.05% cream: 20 to 30 g daily (up to 40 g/day in large body mass) applied twice daily to the entire body surface (sparing the face) until clinical disease control (no new blisters, pruritus arrested, existing erosions re-epithelializing; typically 15–21 days).
   • Tapering schedule: Once controlled, clobetasol is reduced to once daily for 1 month, then alternate days for 1 month, then twice weekly for 2 to 3 months, aiming for complete discontinuation by month 6 to 12.
2. Systemic Corticosteroids (When Topicals Impractical):
   • Oral prednisolone 0.5 mg/kg/day for moderate BP; 0.75 mg/kg/day for severe extensive BP. Doses >0.75–1.0 mg/kg/day increase mortality without therapeutic benefit and are strictly discouraged.
3. Anti-Inflammatory Antibiotic Regimen (Mild / Maintenance BP):
   • Doxycycline (200 mg/day). The UK multicentre BLISTER trial (Williams et al., The Lancet 2017) found doxycycline non-inferior to oral prednisolone (0.5 mg/kg/day) for short-term blister control (74% vs 91% with 3 or fewer blisters at 6 weeks; pre-specified non-inferiority margin 37%), with about half the rate of severe, life-threatening, or fatal treatment-related adverse events at 52 weeks (18% vs 36%). Nicotinamide is sometimes added in practice but was not part of the trial.
4. Steroid-Sparing Immunosuppressants:
   • Methotrexate: 7.5 to 15 mg weekly (with folic acid 5 mg weekly) is highly effective in elderly patients unresponsive to or dependent on topical steroids.
   • Azathioprine: 1.0–2.5 mg/kg/day (guided by TPMT activity).
   • Mycophenolate Mofetil: 2.0–3.0 g/day.
5. Targeted Biologics for Refractory Disease:
   • Omalizumab (Anti-IgE monoclonal antibody): 300 mg subcutaneous every 2 to 4 weeks. Neutralizes circulating IgE autoantibodies against BP180 and downregulates Fc-epsilon-RI receptors on eosinophils, resolving intractable pruritus and blistering.
   • Dupilumab (Anti-IL-4R-alpha monoclonal antibody): 600 mg loading dose, then 300 mg subcutaneous every 2 weeks. Blocks IL-4 and IL-13 signaling, interrupting the Th2 axis driving tissue eosinophilia and B-cell class switching.

Mucous Membrane Pemphigoid (MMP)

Mucous membrane pemphigoid (formerly cicatricial pemphigoid) is an umbrella term for chronic, subepithelial autoimmune blistering dermatoses characterized by a predilection for mucous membranes and a relentless propensity to heal with cicatricial scarring and irreversible architectural distortion.

Clinical Manifestations by Anatomical Site

• Oral Mucosa (85–90%): Most frequent site. Presents as desquamative gingivitis (friable, bright erythematous, glazed gingiva that bleeds easily upon tooth brushing) alongside painful erosions on the buccal mucosa, hard and soft palate, and tongue. Oral lesions heal with minimal scarring.
• Ocular Mucosa (60–70%): A sight-threatening medical emergency. Begins as insidious, unilateral or bilateral conjunctivitis, foreign-body sensation, and dry eyes. Progresses to subepithelial conjunctival fibrosis, shortening of the conjunctival fornices, symblepharon (fibrous adhesions connecting the palpebral conjunctiva of the eyelid to the bulbar conjunctiva of the eyeball), ankyloblepharon (fusion of upper and lower eyelids), trichiasis (inward-turning eyelashes that abrade the cornea), corneal neovascularization, corneal ulceration, and complete, irreversible blindness.
• Laryngeal & Pharyngeal (15–20%): Chronic hoarseness, stridor, and progressive supraglottic stenosis. Cicatricial airway narrowing constitutes an acute, life-threatening emergency necessitating urgent emergency tracheostomy.
• Esophageal (5–10%): Web formation and circumferential fibrous strictures causing progressive dysphagia.
• Genital Mucosa (15%): Vaginal stenosis, introital narrowing, labial fusion, or urethral meatal stenosis.
• Cutaneous Lesions (25–30%): Tense blisters occurring primarily on the head, neck, and scalp; can manifest as the localized Brunsting-Perry cicatricial pemphigoid variant (scarring plaques on the head and neck without mucosal disease).

Molecular Antigens and Paraneoplastic Risk

• Autoantibody Targets: Heterogeneous; includes BP180 (especially the carboxy-terminal domain and NC16A), BP230, Alpha-6-Beta-4 Integrin (α6β4) (strongly linked to severe, isolated ocular cicatricial pemphigoid), and Laminin 332.
• The Anti-Laminin 332 Malignancy Trap: Approximately 25% to 30% of patients with anti-laminin 332 MMP harbor an underlying occult solid-organ malignancy, most frequently adenocarcinoma of the stomach, colon, lung, pancreas, or genitourinary tract (endometrium, ovary, prostate). The autoantibody binds laminin 332 overexpressed on invasive adenocarcinoma cells, inducing cross-reactive autoimmunity against the mucosal BMZ. Mandatory clinical rule: Every newly diagnosed patient with anti-laminin 332 pemphigoid must undergo immediate, rigorous age- and sex-appropriate malignancy screening, including thoracic, abdominal, and pelvic CT scans, gastrointestinal endoscopy, and tumor marker profiling.

European Risk Stratification and Therapy

• Low-Risk MMP (Oral mucosa or skin only, without scarring): Managed with high-potency topical corticosteroids (clobetasol ointment in dental trays), intralesional triamcinolone, dapsone (50–150 mg/day), or doxycycline.
• High-Risk MMP (Ocular, laryngeal, pharyngeal, esophageal, or anogenital involvement): High risk of irreversible blindness or airway asphyxiation. Demands urgent multidisciplinary care (dermatology, ophthalmology, ENT) and aggressive first-line systemic immunosuppression:
  • Oral Cyclophosphamide (1.5 to 2.0 mg/kg/day) or pulsed IV cyclophosphamide combined with oral prednisolone (1.0 mg/kg/day).
  • Rituximab (1000 mg IV on days 0 and 14) is increasingly utilized as preferred first-line therapy for severe refractory ocular and laryngeal MMP.

Epidermolysis Bullosa Acquisita (EBA)

Epidermolysis bullosa acquisita is a rare, acquired, non-hereditary subepidermal blistering disease mediated by IgG autoantibodies targeting Type VII collagen, the key molecular constituent of anchoring fibrils within the sub-lamina densa.

Clinical Phenotypes of EBA

1. Classical Mechanobullous (Non-Inflammatory) EBA:
   • Clinically mimics hereditary dystrophic epidermolysis bullosa (DEB) and porphyria cutanea tarda (PCT).
   • Marked mechanical skin fragility: Minor shearing trauma produces tense blisters and erosions localized strictly to trauma-prone extensor surfaces (dorsa of hands, knuckles, elbows, knees, pretibial shins, heels).
   • Lesions heal with conspicuous atrophic scarring, post-inflammatory hyperpigmentation, nail dystrophy, loss of nail plates, and abundant milia cysts.
2. Inflammatory (Bullous Pemphigoid-like) EBA:
   • Widespread tense bullae arising on erythematous, urticarial plaques with intense pruritus, clinically and histologically indistinguishable from bullous pemphigoid.
3. Mucous Membrane EBA:
   • Cicatricial mucosal involvement mimicking MMP, leading to esophageal strictures, conjunctival scarring, and laryngeal stenosis.
4. Brunsting-Perry Variant:
   • Blistering and scarring alopecia localized to the head and neck.

Systemic Associations

EBA is strongly associated with Inflammatory Bowel Disease (IBD), particularly Crohn's disease, in up to 30% of patients. Type VII collagen is expressed in human intestinal basement membrane; chronic transmural gut inflammation promotes antigen presentation and cross-reactive autoantibody production against dermal anchoring fibrils.

Diagnostic Distinction: Salt-Split Skin & Serration Analysis

Distinguishing inflammatory EBA from bullous pemphigoid is essential because EBA is notoriously refractory to conventional therapy:

• Direct Immunofluorescence (DIF): Shows continuous linear IgG and C3 along the BMZ. High-resolution examination reveals a u-serrated pattern in EBA (staining lines the base of the dermal papillae in continuous downward-facing concave arches), whereas BP displays an n-serrated pattern.
• 1M NaCl Salt-Split Skin IIF: Cleaves skin through the lamina lucida. Because Type VII collagen anchoring fibrils reside beneath the lamina densa in the sub-lamina densa, EBA autoantibodies bind exclusively to the dermal floor (the bottom of the split). In contrast, BP autoantibodies bind to the epidermal roof.
• Anti-Type VII Collagen ELISA: Confirms circulating IgG targeting the NC1 domain.

Subepidermal Autoimmune Blistering Diseases Comparison Table